3370. PCR. HPV 28 (genotyping 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82, 6, 11, 40, 42, 43, 44, 54, 61, 70, U/G scraping, qualitative determination)

Detection of the human papillomavirus (HPV) pathogen is performed using real-time polymerase chain reaction (PCR), during which the viral DNA is analyzed in a biological sample. This method identifies the presence of specific virus types (19 high-risk types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 and 9 low-risk types: 6, 11, 40, 42, 43, 44, 54, 61, 70), and their genotyping is carried out. Determining the virus type allows for assessment of the risk level for neoplasia development and differentiation between viral persistence and a new infection during dynamic monitoring.

To detect the pathogen, the polymerase chain reaction (PCR) method is used, which enables the identification of viral DNA. The principle of the method is based on amplifying the number of copies of a DNA fragment specific to the pathogen. Polymerase chain reaction (PCR) is a molecular diagnostic method that allows the detection of the pathogen's genetic material at early stages of the disease. It is characterized by high diagnostic sensitivity and specificity, rapid turnaround time, and accessibility. A key feature of the method is its ability to detect viral DNA even when present in very low concentrations in the tested biological material. Indications for use: - during cervical cancer screening in women over the age of 25-30 (as an additional test); - during monitoring of patients infected with HPV; - in the treatment of cancer and precancerous conditions associated with HPV.

• Scrapes from various sites depending on the test

Women